ArticleFrontiers in cellular and infection microbiology2026
Revisiting an overlooked biomarker: CSF-IgA demonstrates significant diagnostic value for viral encephalitis in a case-control study.
Article in Frontiers in cellular and infection microbiology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
11 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background: Viral encephalitis (VE) is a serious central nervous system infection, yet its diagnosis is challenged by non-specific clinical manifestations, low pathogen detection rates, and often normal routine cerebrospinal fluid (CSF) findings. The diagnostic potential of CSF immunoglobulin A (CSF-IgA) has been largely overlooked. This study aimed to evaluate the diagnostic value of CSF-IgA for VE. Methods: This single-center, retrospective case-control study analyzed data from 233 patients with VE and 80 symptomatic controls, collected over a 15.5-year period (January 1, 2010 to June 30 2025). A multivariable logistic regression model was constructed using variables that were significant in univariate analysis (p < 0.05). Model performance was rigorously evaluated in the overall cohort for discrimination (area under the receiver operating characteristic curve, AUC), calibration (using calibration plots and the Brier score), and clinical utility (via decision curve analysis). The model was further validated in a predefined subgroup of VE patients (n=50) with normal routine CSF findings, defined as normal CSF pressure, cell count, total protein, albumin, glucose, and chloride levels. Results: The final parsimonious diagnostic model retained three robust predictors: CSF-IgA (OR 2.56, 95% CI: 1.73-4.06), CSF white blood cell count (OR 1.45, 95% CI: 1.25-1.76), and serum albumin (OR 0.81, 95% CI: 0.71-0.91). It demonstrated excellent discrimination in the overall cohort (AUC 0.933, 95% CI: 0.913-0.955), was well-calibrated (Brier score = 0.091), and provided superior net benefit across a wide threshold probability range. Importantly, robust performance was maintained in the clinically challenging subgroup with normal routine CSF parameters (AUC 0.812, 95% CI: 0.730-0.873; Brier score = 0.171). Conclusions: CSF-IgA may serve as a promising adjunctive biomarker for viral encephalitis. A diagnostic model incorporating CSF-IgA showed good performance, even in atypical cases with normal routine CSF profiles, indicating its potential utility as an auxiliary tool for early VE diagnosis. However, given the single-center retrospective design, prospective external validation is warranted before routine clinical implementation.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.